One approach to clinical decision-making requires the integration of the best available research evidence with individual clinical expertise and patient values, and is known as evidence-based medicine (EBM). In clinical decision-making with the current best evidence, systematic reviews have an important role. This review article covers the basic principles of systematic reviews and meta-analyses, and their role in the process of evidence-based decision-making. The problems associated with traditional narrative reviews are discussed, as well as the way systematic reviews limit bias associated with the assembly, critical appraisal and synthesis of studies addressing specific clinical questions. The relevant steps in writing a systematic review from the formulation of an initial research question to sensitivity analyses in conjunction with the combined analysis of the pooled data are described. Important issues that need to be considered when appraising a systematic review or meta-analysis are outlined. Some of the terms that are used in the reporting of systematic reviews and meta-analyses, such as relative risk, confidence interval, Forest plot or L'Abbé plot, will be introduced and explained.
Introduction
Shortage of resources is a common constraint in almost every industry. In healthcare, it affects the macro-level, meso-level and micro-level and each anaesthesia department and individual anaesthetist accordingly. One important resource that can be affected is information, and failure to harvest it effectively will have a negative impact on the quality of clinical care. Evidence-based medicine (EBM) with its claim to apply the 'current best evidence to decisions on the care of individual patients' 1 has become widely accepted as the basis for clinical decision-making.
As the amount of information available to support clinical decisions increases, so the importance of systematic reviews that can evaluate and summarize the evidence grows. The success of evidence-based practice is dependent upon access to reviews of quality. The value of each piece of evidence is determined by the quality of its science, and this can be ranked using a classification from the Oxford Centre of Evidence Based Medicine, using a hierarchy that has gained widespread acceptance (http:// www.cebm.net/index.aspx?o=1025).
With the assistance of an algorithm that incorporates a rank of quality, clinicians should first search for highly ranked systematic reviews and, if these or other sources of evidence are unavailable, to try and locate case series, expert opinion without formal quality-assessed recommendations or even case reports. The last can be of great assistance when researching how an uncommon problem might be managed. It is not only clinicians who might use information that has been appropriately weighed and summarized, well informed patients also seek access to the same evidence and may use it as the basis for their decision-making. This in turn creates pressure on the clinician, who risks embarrassment if not up-to-date.
Critical clinical thinking demands that we continually reassess our practice and question the analysis of risk versus benefit, even for interventions that we consider to be routine. On a departmental level, new devices and pharmacological innovation are increasingly undergoing a thorough assessment before widespread use is encouraged. Aspects of patient safety as well as budget restraints foster these developments. Systematic reviews are one way of dealing with the wealth of information about new and traditional interventions in patient care. Although most practising anaesthetists will not write systematic reviews, some understanding of the quality assessment process is needed before their message can be used to support clinical care and influence the lives of individual patients.
Whether a narrative review article has a broader (such as 'anaesthetic implications of pregnancy') or narrower (such as 'coagulation disorders during pregnancy') scope, it is the quality of the analysis that determines its success. It is the reviewer who chooses what to include and what to omit, and in the exercise of this choice lies the potential for bias. Unless the reader is well versed in the topic, he/she will not recognize the omission of key data. It is the integrity of the reviewer that determines whether interpretation is balanced and fair, or whether it is skewed to reflect a personal opinion. Reasons for bias are varied; it could be that reviewers are out of touch with everyday experience and not representative of current best clinical practice or they may have a research interest in a specific clinical topic and be disinclined to acknowledge the work done by others, while neglecting the weaknesses and limitations of their own. The popular saying 'ask three different experts and you will get three different answers' nicely describes this inherent threat of narrative reviews. But even when a reviewer aims to provide unbiased and objective analysis, if the number of available trials exceeds three or four, it is difficult to digest and weigh all the data, and pool the results to provide a balanced interpretation. The alternative is to provide formal summary statistics within a meta-analysis or other rigorous quantitative assessment and reduce the risk of expert bias. Some differences between narrative and systematic reviews (which may not be exclusively valid for one or the other category) are depicted in Table 1 .
The special need for systematic reviews
If only a few original clinical research articles were published each year, it would be quite easy to keep up to date and frame views from the available evidence. This is difficult in the era of the 'information explosion' when Internet access can find an ever greater variety of sources. A 'quick look in MEDLINE' can yield several hundred results and can confuse. How does a clinician select what to read? The selection of a few random samples might introduce a considerable retrieval bias, but to thoroughly screen 500 or more potentially relevant reports is unrealistic.
Consider, for example, whether a background infusion in association with an opioid patient-controlled analgesia (PCA) pump is beneficial or not. Using the MEDLINE search terms intravenous AND PCA AND morphine AND background AND infusion, and the restriction to randomized controlled trials (http://www.pubmed.org, last accessed 10 December 2008) would yield 34 results. Of these, two trials (no. 10 and no. 14) would, at first sight, appear particularly relevant. However, the results conflict, as, although the country and setting -both trials were performed in cardiac surgery patients in Turkeyseem identical, the conclusion of one trial published in 2003 stated 'PCA with morphine effectively controlled postoperative pain after cardiac surgery. The addition of a background infusion of morphine did not enhance analgesia and increased morphine consumption'. 2 In contrast, the second trial published 1 year later concluded 'morphine PCA effectively controlled postoperative pain after cardiac surgery. The addition of a background infusion of morphine enhanced analgesia and increased morphine consumption'. 3 Interestingly, both trials were published in the same journal and under the same subsection, 'Cardiothoracic Anesthesia, Respiration and Airway'. Apparent conflicts of this nature provide the rationale for 'secondary research', which takes a thorough look at study design and research methodology. Secondary research, in this context, is based on previously acquired results from primary research. Systematic reviews are one form of secondary research, and can be well done or flawed, giving rise to misleading conclusions and bringing the reputation of systematic reviews into question. As with clinical research in general, the presence of one or two bad apples does not mean that the entire barrel 764 Kranke should be discarded. The best systematic reviews and meta-analyses are recognizable because, like clinical trials, they are performed according to well established standards. 4, 5 Those of quality should assist clinicians in interpreting and evaluating conflicting data. Unfortunately, systematic reviews can also conflict in their interpretation, and the clinician may find it helpful to be able to distinguish between the best and the rest. [6] [7] [8] [9] Common definitions Systematic review A systematic review is a literature review focused on a single question that tries to identify, appraise, select and synthesize all high-quality research evidence relevant to that question (http://en.wikipedia.org/wiki/Systematic_ review).
In qualitative systematic reviews, there are no calculations of summary effect sizes (see below).
Meta-analysis
A meta-analysis (quantitative systematic review) is a statistical technique for amalgamating, summarizing and reviewing primary quantitative research. Performing a meta-analysis means that selected parts of the results of primary studies are entered into a database and this 'meta-data' is then 'meta-analysed' descriptively and then inferentially, like any other data to test certain hypotheses. The result of such an analysis is a more powerful estimate of the true effect size than those derived from a single study.
The content and production of a systematic review What should be the scope of the review and which questions should be answered?
A systematic review, in contrast to the narrative review, usually starts with a clinician or researcher wanting to answer a specific question. It is argued that the answer to this question should not be self-evident, but, in the process of compiling up-to-date trials, the question sometimes evolves to a surprising degree. The outcome might provide an unanticipated insight that challenges perceived wisdom and introduces controversy where all previously was accepted. The PICO rule (patient, intervention, comparator and outcome) is a useful tool in the contexts of both evidence-based decision-making and systematic reviews. It provides a structure to help with the inclusion of the important aspects: Identifying the best intervention is obviously more specific than the question 'Is remifentanil suitable for labour analgesia?' or the less worthy 'Is remifentanil a useful opioid in anaesthesia practice?' Even when the scope is narrow, there will be considerable variation within the trials that are included in the review. For example, the design of these trials will have different lockout intervals, bolus doses, background infusions, timing of the intervention, assessment scales and outcome definitions. Without a clearly framed question, a search for the relevant primary studies based on objective inclusion and exclusion criteria is not feasible.
The next vital step to take is to predefine a study or review protocol. This should identify the objectives and ensure that major decisions with regard to the inclusion or exclusion of relevant publications, and the way missing data are managed, are not made in a subjective way. The presence of predefined rules prevents the reviewer from introducing variation into the handling of different studies, giving consistency to the analysis and increasing confidence in the reader.
Which studies are included and why?
Primary studies that meet predefined inclusion and exclusion criteria are included. These are selected by their relevance to the research question and their methodological quality. Relevance to the research question is of key importance when writing a systematic review. It is for the reviewer to set the threshold for the standard of study design, and trials that meet this standard will be included. Whether it is set high or low will depend on the nature of the research question and on the availability of trials seeking to answer that specific question. The aim to selectively include randomized, controlled, doubleblinded and placebo-controlled trials may not be appropriate if a 'gold standard' already exists. Given such a scenario, clinicians would be more interested to know how the intervention in question (active intervention 'B') compares with the existing gold standard (active intervention 'A'), as they want to know whether it makes sense to introduce a new treatment or continue with the established one. Blinding in clinical trials is worthwhile to prevent subjective assessment and minimize bias. However, this principle is not feasible for all treatments, including some pharmacological interventions to which blinding seems readily applicable. One such example is trials involving methylene blue, which, despite blinding, will invariably reveal its presence to an observer at some stage. Randomization is considered of utmost importance if a treatment effect should be ascribed to a specific intervention. The underlying rationale is that, in any given study, only one variable is under test between the groups, and the difference between the groups should genuinely reflect the effect of the intervention. Ideally, all other aspects of the trial are standardized. Unfortunately, all individuals differ to varying degrees, and unless the distribution of individual characteristics is balanced through the groups, standardization fails, confounding factors appear and bias may result. The best means of ensuring that confounding factors are balanced is through random allocation to groups. Again, there is no dogma that dictates that only randomized trials should be included in a systematic review, even in a review of treatment options. An interested reader may also benefit from a systematic review of case series, especially if better evidence is unavailable. The potential for bias is far greater in reviews of this nature and the issue of bias should be considered by the author in the discussion.
Bias (or: systematic error) can be described as any deviation from the truth that influences the results, or any flaws in the processes leading to such deviation. Some common sources of bias are explained:
(1) Selection bias: a bias in assignment or a confounding variable that arises from study design rather than by chance. A selection bias may occur if the study and control groups are chosen so that they differ from each other by one or more factors that may affect the outcome of the study. Similar effects may also apply to the inclusion of trials in meta-analyses. 10 (2) Language bias: the exclusion from meta-analyses of trials reported in languages other than English may introduce bias and reduce the precision of combined estimates of treatment effects.
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(3) Duplicate publication bias: trial results published in English are more likely to be subject to multiple publication.
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(4) Citation bias/reference bias: trial results published in English are more likely to be cited by other authors. Thus, such reports are more likely to be found by reviewers performing a literature search prior to performing a meta-analysis. 13 (5) Publication bias: this well known source of bias arises from the tendency for researchers and editors to handle the reporting of experimental results that show a significant finding (positive results) differently from results supporting the null hypothesis (negative results) and those that are inconclusive and need further investigation. The researcher may decide that, because the trial has failed to give a significant result, he/she will not submit for publication. Editorial bias occurs when the paper is rejected for publication in favour of another with a significant result. Bias of this nature can lead to an overestimate of the true effect. In an effort to overcome this problem, some medical journals require registration of a trial before it commences so that unfavourable results cannot be withheld from publication so easily and are more visible.
For formal quality assessment of included trials, the Oxford scale may help to give an overview of trial features. 14 This popular five-point scoring system uses three criteria and asks the following questions:
(1) Is the trial randomized (one point). Additional point if the method is given and appropriate? (2) Is the trial double-blind (one point). Additional point if the method is given and appropriate? (3) Were withdrawals and dropouts described and assigned to different treatments (one point)?
Trials that score three points or more are usually considered relatively free of bias and should be trusted. Lower scores in some therapeutic areas have an association with increased treatment effects; they were probably biased. 15, 16 As explained, these categories may not be appropriate if a treatment cannot be blinded. More comprehensive scoring systems exist, but it remains questionable whether these provide any added value to the overall results of the review.
A successful systematic review will have found sufficient trials. One that lacks adequate substrate may conclude that there is insufficient evidence to show whether treatment A is of benefit or even the reverse. This is of no help to clinicians. As a preliminary to conducting a review, it is sound sense to perform pilot searches before inclusion and exclusion criteria are defined. This allows the threshold for eligible trials to be lowered to ensure sufficient evidence to provide at least some information for clinicians.
Which data are extracted and which analyses are performed and displayed? Based on the inclusion and exclusion criteria, a search strategy will be created that hopefully finds all the relevant literature. Obviously, the more sensitive a search algorithm is, the more time it takes to manually search through retrieved articles before deciding which ones should be included. If the pilot search reveals that the literature is limited, then it does not make sense to be too restrictive regarding the search algorithm. Thus, potential relevant articles are not missed and, by screening the hits of the search, the reviewers acquire insight into the background of the research question and can explore links to other topics that might also be relevant. Screening the abstracts identifies irrelevant articles that can be excluded, and, where relevance is equivocal because of insufficient information, full-text articles should be obtained. Selection, as well as the data extraction, is usually done by at least two independent researchers who are familiar with the procedure. In case of a disagreement, a third reviewer is sometimes necessary. It may be worthwhile to blind reviewers to the origin of the article and its authors so that assessment is truly unbiased. If reviewers possess a prior in-depth knowledge of the existing literature and are experts in the field, such a precaution will be ineffective. A flow chart usually highlights this selection process and informs the review reader which primary studies have been excluded and at which stage of the retrieval process (Fig. 1) . Such a flow chart is explicitly encouraged by the PRISMA statement. 17 Apart from methodological features of the included trials, some descriptive data are usually extracted for presentation. This information is usually given in the first table of the systematic review. Efficacy data that are obtained from primary studies can be either dichotomous (how many patients die, for example) or continuous (the mean pain level was 7 on a scale from 0 to 10, with some estimate of variance). The weighted mean could be calculated for groups before and after an intervention (such as falls in blood pressure), and the weighted mean difference would be the difference between start and finish values. For this, though, the difference would usually be calculated not as the difference between the overall start value and the overall final value, but rather as the sum of the differences in the individual studies, weighted by the individual variances for each study. Dichotomous efficacy data in treatment studies are usually combined and presented as relative risk or odds ratio and, like the weighted mean difference, are provided with a (95%) confidence interval (the range of values within which we can be 95% sure that the true value for the whole population lies). Forest plots (Fig. 2) and L'Abbé plots (Fig. 3) help to provide a visual summary of the included data from the primary studies. The Forest plot with relative risks, associated confidence intervals and the attributed weight of each study provides information on the magnitude of effect of each trial and its influence on the pooled statistics. The L'Abbé plot offers insights into the extent to which the investigated population, with its underlying risk, resembles the population of interest (relevant question: is the control event rate comparable or completely different?).
Sometimes publications that include meta-analyses also present sensitivity analyses, testing the robustness of the results under the condition that certain studies (poor quality, small sample size) are excluded. Restricting the pooled analysis to a defined intervention or patient population may also be termed sensitivity analysis and may provide insight into associations between the observed effect and the causative conditions. However, the results should usually be viewed as hypothesis framing and at best as a weak indication of a real causative condition, as all these analyses are post-hoc analyses.
To appreciate whether the results of the meta-analysis are influenced by sources of bias, or whether there are any doubts about the veracity of results of clinical trials, funnel plots are sometimes included in publications. A funnel plot is where some trial-specific effect (odds ratio, relative risk) is plotted against some measure of its precision. Precision may be defined in different ways. One commonly used is the number of participants in a trial, or some function of the standard error (Fig. 4) . If the plot is symmetric, like an inverted V ('funnel'), this is interpreted as demonstrating that there is probably no publication bias. If the plot is asymmetric (Fig. 4) , then publication bias is suspected, suggesting the possibility of unpublished negative trials that might counter the positive findings of a meta-analysis, if only they could be found. Another cause of an asymmetric plot is a systematic difference between smaller and larger studies ('small study effects'). Asymmetry may also arise from the use of an inappropriate or variable effect measure.
However, there is great scepticism as to whether such tools make sense and there is some empirical evidence that funnel plots may be misleading. 18, 19 Clinicians should not be afraid of adopting the results of metaanalyses into their practice simply because there is some asymmetry in the funnel plot. Rather they should ask the following questions in order to ascertain whether the results of a meta-analysis matter to their patients:
(1) Are the patients in the trials like mine? (2) Are the inclusion criteria sensible? (3) Do the outcomes make sense? (4) Are they useful and do they matter to my patients?
For the creation of the summary statistics, various models (fixed versus random-effects model) based on the underlying assumptions may be used. Details regarding the computing of these summary statistics will not be Systematic reviews for clinical decision-making 767 Flow diagram as suggested by the PRISMA statement on the reporting of items for systematic reviews. On each stage (from 'Identification', 'Screening', 'Eligibility' and 'Included'), the appropriate number of relevant studies is reported to ensure transparency as far as the inclusion and exclusion of trials is concerned.
described here. However, one common misconception merits a brief discussion.
Methods of fixed-effects meta-analysis are based on the mathematical assumption that a single common (or 'fixed') effect underlies every study in the analysis, so that, if we were doing a meta-analysis of odds ratios, we would assume that every study is estimating the same odds ratio. There is no (statistical) heterogeneity among the studies. Given this assumption, every study would yield an identical result, provided all trials were infinitely large. A random-effects analysis makes the assumption that individual studies are estimating different treatment effects. They have a distribution with some central value and some degree of variability. The idea of a randomeffects meta-analysis is to gain insight into this distribution of effects across the included trials.
It is widely held that random-effects summary effect estimates are more conservative (i.e. produce less 'enthusiastic' treatment effects) than fixed-effects summaries in epidemiological meta-analysis. This view is based on the fact that random-effects summaries have higher estimated variances and, consequently, wider confidence intervals than fixed-effects summaries when there is evidence of appreciable heterogeneity among the results from the individual studies. In such cases, however, the random-effects point estimates are not invariably closer to the null value nor are their P values invariably larger than those of fixed-effects summaries. Thus, randomeffects summaries are not predictably more conservative. 21 As an example, the reader may have a look at the simulation of a meta-analysis (magnesium for acute myocardial infarction) where the random-effects summaries are less conservative in both of these alternative senses and possibly more biased than the fixed-effects summaries (Fig. 5a,b) .
The common understanding is that a random-effects model answers the question on the basis of the studies that are examined:
(1) Is it possible to comment that the treatment or the exposure will produce a result?
Whereas the fixed-effects model, if applied to calculate summary statistics, answers the question:
(1) Whether the studies included in the meta-analysis show that the treatment or exposure produced the effect on average.
For practical purposes, it is reasonable to remember that if heterogeneity does not play a role, fixed and randomeffects models deliver the same results (Fig. 6 ). 
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Forest plot of trials investigating metoclopramide in the prevention of postoperative nausea and vomiting in children undergoing tonsillectomy. Relative risk (risk ratio) with the corresponding 95% confidence interval (95% CI) is represented by the squares with connected lines. The sizes of the squares relate to the sample size. Whereas the summarized results (subtotals -distinct dose groups, as well as totals -all results irrespective of the doses used) are displayed by diamonds, the span of the diamond indicates the CI. The sample is a subset of a previous systematic review investigating interventions to prevent postoperative vomiting in children undergoing tonsillectomy.
Based on these considerations, some others suggest that 'the discussion of when to use random effects and when to use fixed effects in computing summary estimates should be replaced by a discussion of whether summary estimates should be computed at all when the studies are not methodologically comparable, when their results are discernibly heterogeneous, or when there is evidence of publication bias.' 20 This discussion adds to the ongoing debate of whether large and small trials should be simply lumped together for the purpose of a meta-analysis. There are no fixed rules as to which heterogeneity of the sample size should be considered homogeneous enough to pool the data in order to obtain a summary point estimate. However, if a graphical display, such as Forest plots, L'Abbé plots or Funnel plots, suggests that the trial's size may be an important determining factor for the observed efficacy (as is the case in Fig. 5a, b) , it may be wise to perform subgroup analyses (sensitivity analyses) to obtain estimates for the magnitude of this difference. 21 What to do with the result of systematic reviews? Systematic reviews encompass the first three principles of evidence-based practice:
(1) ask (a clinically relevant question) (2) search (for external evidence) (3) and appraise (the retrieved evidence).
The fourth and fifth principles, 'Apply' (the evidence) and 'Evaluate' (the obtained results), are the logical next steps. This can only be done by the practising clinician or by an executive decision within the healthcare system (for example, hospitals or anaesthesia departments). Researchers of the systematic reviews can only choose the right format to disseminate their results in the most effective way.
As described previously, a quality assessment may help clinicians to decide whether the results of a systematic review should be trusted and this may depend on the availability of primary studies rather than the methodology applied for the systematic review.
The following questions may help to get a more precise picture of a systematic review:
(1) Did the review address a clearly focused question that is also my own clinical question? (2) Did the review include the type of studies that are most likely to deliver unbiased results? (3) Did the reviewers make efforts to identify all relevant primary studies? (4) Did the reviewers assess the quality of the included studies and was the quality acceptable to guarantee valid results?
Systematic reviews for clinical decision-making 769 Intravanous magnesium for acute myocardial infarction (primary version) 01 magnesium vs placebo on mortality 03 mortality by dose of magnesium
Funnel plot of trials investigating intravenous magnesium for acute myocardial infarction. Funnel plots sometimes help determine how effective an intervention is and how reliable that effect is. Results from randomized controlled trials (RCTs) vary. The funnel plot for RCTs of an intervention that has a consistent effect will be triangular (looks like an 'inverted funnel', or a decorated Christmas tree). RCTs that produce precise results are plotted at the top and imprecise results are plotted at the bottom. Results with the same precision are plotted on the same horizontal level. The averaged result from each level, given enough studies, will be the same. (a) Calculation of a summary statistic using a random-effects model in a simulation of a meta-analysis of selected trials investigating intravenous magnesium for acute myocardial infarction. The risk ratio (relative risk) was calculated with a random-effects model and resulted in a point estimate of 0.79 (95% CI 0.68-0.92). (b) Calculation of a summary statistic using a fixed-effects model in a simulation of a meta-analysis of selected trials investigating intravenous magnesium for acute myocardial infarction. Note: the risk ratio (relative risk) was calculated with a fixed-effects model and resulted in a point estimate of 0.99 (95% CI 0.94-1.04).
(5) In the case of a pooled analysis: was it reasonable to combine study results or were 'apples' compared with 'oranges'? (6) What are the main results (direction)? (7) How precise are the results (width of the confidence intervals and heterogeneity)? (8) Were all important outcomes considered (favourable outcomes as well as adverse outcomes) and is the outcome mentioned in the focused clinical question (PICO principle) among the outcomes discussed in the review?
However, the most important questions, as far as the implementation process is concerned, are:
(1) Can the results be applied to my local population? Or, to be more precise: is the patient I want to treat similar enough to the studied population for the results to apply to him/her? (2) Should practice or policy change as a consequence of the recommendation of the review?
These are typical questions in the daily practice of EBM. As they are context sensitive, there is no general valid 'yes' or 'no' answer that applies to all patients and populations, even if there is a clear recommendation in a systematic review that supports one intervention. Economic considerations as well as skills and availability of resources (equipment, time, personnel) may play an important role in this decision.
As a general simple rule, policy changes are most likely to affect costs and outcome of healthcare if a rare condition associated with great costs and severe clinical outcome is concerned, or if a frequent condition with small costs and minor clinical outcome is the focus (since frequent conditions associated with great costs are usually streamlined at an earlier stage).
How to find systematic reviews? There are numerous ways to find high-quality systematic reviews and a good start is to consult the Cochrane Library (http://cochrane.org/). However, full-text versions of reviews published in the Cochrane Library are not available to all individuals and institutions. Furthermore, other systematic reviews published in a journal format may be more suitable, regarding the scope and patient population and perhaps readability. Therefore, a simple and universally applicable approach is to use the clinical queries link on PubMed in order to identify systematic reviews. Starting with http://www.pubmed.org, the Clinical Queries are one 'mouse-click' away and the interested clinician is able to insert the relevant search terms in the section 'Find Systematic Reviews' and then press 'go' to activate the search engine (http://www.nlm.nih.gov/bsd/pubmed_ subsets/sysreviews_stra tegy.html).
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How to implement the results of systematic reviews? Creating standard operating procedures (SOPs) to guide and streamline clinical decision-making has become very Systematic reviews for clinical decision-making 771 Calculation of a summary statistic using a random versus a fixed-effects model in a meta-analysis of trials investigating palonosetron to prevent postoperative nausea and vomiting. Note: the risk ratio (relative risk) resulted in a similar point estimate of 0.68 (95% CI 0.57-0.80) and 0.67 (95% CI 0.57-0.80), if calculated using a random or fixed-effects model, respectively. popular in recent years. They usually represent a 'how-todo' manual for the busy clinician who cannot keep up to date in every area of expertise and represent a form of documentation of the process quality, a vital part of quality assurance. However, usually, these guidelines are 'expert guidelines', compiled by the head of the department or another expert setting out current ideas regarding diagnosis or treatment in a hospital. These would be much improved if they were supported by scientific evidence. Systematic reviews provide an excellent way of doing this. Authors of the guidelines are not forced to quote numerous references but are able to link a statement to the current available evidence. If new evidence emerges (for example, an updated systematic review), this can be easily inserted and, in case a recommendation is changed, the appropriate modification can be made.
Conclusion
Systematic reviews apply scientific strategies to provide a transparent summary of all studies addressing a specific question, thereby allowing account to be taken of the whole range of relevant findings on a particular topic. Meta-analysis, which may or may not accompany a systematic review, can increase power and precision of estimates of treatment effects by pooling the results of primary studies. People working in the field of anaesthesia and critical care should understand the fundamental principles of systematic reviews and meta-analyses, including the ability to apply critical appraisal not only to the methodologies of review articles, but also to the applicability of the results to their own patients, for clinical decision-making and to base policy changes on the best available and most appropriate resources. A more comprehensive review of this topic can be found in books 23 and detailed review articles. 24, 25 Key issues
(1) Systematic reviews are considered of paramount importance in the practice of EBM. (2) Systematic reviews usually have a narrower remit than narrative reviews and typically address one distinct research question. (3) In contrast to systematic reviews, which represent a research paper, narrative reviews usually provide a better overview of a broader topic, including epidemiological findings and some relevant background information; they are usually more 'reader-friendly'. (4) Questions that are addressed in systematic reviews should typically contain the following components (PICO principle): patient; intervention; comparator; and outcome. (5) In common with every research methodology, inherent weaknesses associated with systematic reviews and especially poor execution may give misleading results. (6) Therefore, before implementing the results of systematic reviews, clinicians should check whether the methodology applied was appropriate and whether the investigated population in the included clinical trials resembles their patients.
